CAR T-Cell Therapy in Multiple Myeloma : Episode 10
The Future of CAR-T: Advancing Myeloma Treatment Strategies
Panelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
How do you see the role of chimeric antigen receptor (CAR) T-cell therapy evolving for earlier lines of treatment in multiple myeloma? What advances are you most excited about for patients with standard-risk disease?
Dr Castaneda: Ask Raja:
From your perspective, how has multidisciplinary collaboration in the use of CAR T-cell therapy improved patient care and outcomes?
Recent Videos
Related Content
